Kymera Therapeutics, Inc. (KYMR) files for IPO.

IPO of Kymera Therapeutics. Inc. (KYMR) will take place on August 20, 2020. Kymera Therapeutics is a biopharmaceutical company. It develops new small molecule therapeutic agents that selectively destroy disease-causing proteins, using Pegasus, company’s proprietary targeted protein degradation platform. It enables to discover highly selective small molecule protein degraders with potent activity against disease-causing proteins throughout the body. 

Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities are the joint bookrunners on the deal.